Table 1.
Characteristics of the cohort and receipt of bone density testing at baseline among women initiating aromatase inhibitor therapy in 2002–2008, N=9138
| N (%) | Unadjusted proportion of women with bone density testing |
P value* | Adjusted Odds Ratio (95% Confidence Interval*) |
P value† | |
|---|---|---|---|---|---|
| 9138 | 41.6 | ||||
| Age | <0.001 | ||||
| 51–59 | 2748 (30) | 44.5 | 1.00 | - | |
| 60–63 | 2168 (24) | 45.3 | 1.03 (0.91 to 1.15) | 0.66 | |
| 64–68 | 1940 (21) | 41.1 | 0.85 (0.75 to 0.96) | 0.01 | |
| 69+ | 2282 (25) | 34.9 | 0.64 (0.56 to 0.72) | <0.001 | |
| Census Region | <0.001 | ||||
| Northeast | 1999 (22) | 37.0 | 1.00 | - | |
| Midwest | 992 (11) | 48.6 | 1.83 (1.57 to 2.12) | <0.001 | |
| South | 1719 (19) | 45.2 | 1.26 (1.06 to 1.50) | 0.009 | |
| West | 4428 (48) | 40.1 | 1.20 (1.04 to 1.39) | 0.01 | |
| Year first dose of AI | <0.001 | ||||
| 2002 | 658 (7) | 26.6 | 1.00 | - | |
| 2003 | 650 (7) | 36.2 | 1.52 (1.20 to 1.94) | <0.001 | |
| 2004 | 1341 (15) | 41.5 | 1.97 (1.60 to 2.44) | <0.001 | |
| 2005 | 1833 (20) | 45.6 | 2.26 (1.84 to 2.78) | <0.001 | |
| 2006 | 2048 (22) | 44.1 | 2.16 (1.76 to 2.65) | <0.001 | |
| 2007 | 2250 (25) | 41.4 | 1.94 (1.58 to 2.39) | <0.001 | |
| 2008 | 358 (4) | 44.7 | 2.02 (1.53 to 2.68) | <0.001 | |
| Charlson Comorbidity Index* | 0.02 | ||||
| 0 | 8242 (90) | 41.2 | 1.00 | - | |
| 1 | 729 (8) | 46.8 | 1.28 (1.09 to 1.50) | 0.002 | |
| 2 | 114 (1) | 37.7 | 1.05 (0.71 to 1.57) | 0.80 | |
| ≥3 | 53 (1) | 35.9 | 0.87 (0.49 to 1.56) | 0.64 | |
| Proton pump inhibitor in year before AI | 0.006 | ||||
| No | 8386 (92) | 42.0 | 1.00 | - | |
| Yes | 752 (8) | 36.8 | 0.86 (0.73 to 1.00) | 0.054 | |
| Bisphosphonates in year before AI | <0.001 | ||||
| No | 8067 (88) | 40.8 | 1.00 | - | |
| Yes | 1071 (12) | 47.6 | 1.33 (1.16 to 1.51) | <0.001 | |
| Tamoxifen use before AI | 0.054 | ||||
| No | 7503 (82) | 42.0 | 1.00 | - | |
| Yes | 1635 (18) | 39.5 | 0.86 (0.76 to 0.97) | 0.01 | |
| Insurance product | <0.001 | ||||
| Health maintenance | 1681 (18) | 30.5 | 1.00 | - | |
| Preferred provider | 5772 (63) | 43.9 | 1.90 (1.69 to 2.15) | <0.001 | |
| Point of service/fee-for- | 1089 (12) | 39.7 | 1.61 (1.36 to 1.91) | <0.001 | |
| Other | 596 (7) | 53.9 | 3.26 (2.67 to 3.99) | <.001 | |
| % with high school degree in zip code of residence, quartiles | <0.001 | ||||
| Quartile 1 (lowest) | 1945 (21) | 36.9 | 1.00 | - | |
| Quartile 2 | 1854 (20) | 42.1 | 1.33 (1.16 to 1.53) | <0.001 | |
| Quartile 3 | 2151 (24) | 41.6 | 1.32 (1.15 to 1.52) | <0.001 | |
| Quartile 4 (highest) | 2230 (24) | 45.6 | 1.54 (1.31 to 1.80) | <0.001 | |
| Unknown | 958 (10) | 40.8 | 1.04 (0.84 to 1.28) | 0.74 | |
| % African Americans in zip code of residence, quartiles | 0.04 | ||||
| Quartile 1 (lowest) | 1945 (21) | 43.2 | 1.00 | - | |
| Quartile 2 | 2158 (24) | 43.2 | 1.00 (0.87 to 1.14) | 0.95 | |
| Quartile 3 | 2115 (23) | 39.1 | 0.82 (0.71 to 0.94) | 0.003 | |
| Quartile 4 | 1962 (21) | 41.3 | 0.91 (0.78 to 1.05) | 0.20 | |
| Unknown | 958 (10) | 40.8 | 1.04 (0.84 to 1.28) | 0.74 | |
| % Hispanics in zip code of residence, quartiles | <0.001 | ||||
| Quartile 1 (lowest) | 1683 (18) | 45.0 | 1.00 | - | |
| Quartile 2 | 1980 (22) | 43.9 | 1.00 (0.86 to 1.16) | 0.98 | |
| Quartile 3 | 2301 (25) | 41.3 | 0.99 (0.84 to 1.17) | 0.90 | |
| Quartile 4 | 2216 (24) | 37.6 | 1.09 (0.90 to 1.33) | 0.36 | |
| Unknown | 958 (10) | 40.8 | 1.04 (0.84 to 1.28) | 0.74 | |
*
Using the chi square test.
†
Using logistic regression and adjusting for all variables in the table.
AI=Aromatase inhibitor